Physician profile
Christopher James Gamble
NPI 1487609277
$7,396.67
in general payments reported to CMS, 2019-2025
50 companies · $599 in 2025
The $599 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $492 · 2021: $1,008 · 2022: $1,111 · 2023: $1,495 · 2024: $1,783 · 2025: $599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,877.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,373.42 | 2020-2025 | |
| Gilead Sciences, INC. | $715.51 | 2019-2025 | Descovy |
| Viiv Healthcare Company | $578.42 | 2022-2025 | Apretude |
| Boehringer Ingelheim Pharmaceuticals, INC. | $461.00 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $349.99 | 2019-2025 | Gardasil 9, Vaxelis, Capvaxive |
| Lilly USA, LLC | $334.56 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $322.06 | 2019-2025 | Prolia, Evenity, Otezla |
| Pfizer INC. | $300.45 | 2019-2025 | |
| Glaxosmithkline, LLC. | $267.22 | 2019-2024 | Shingrix, Arexvy, Bexsero |
| Novo Nordisk INC | $243.82 | 2019-2025 | Ozempic, Rybelsus |
| Hologic Sales and Service, LLC | $225.36 | 2020-2024 | Aptima, Thinprep 2000 Processor |
| Astellas Pharma US INC | $215.88 | 2019-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $195.32 | 2019-2024 | Airsupra |
| Sanofi-Aventis U.S. LLC | $193.31 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $165.04 | 2019-2024 | Spravato, Xarelto |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Gamble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.